133 related articles for article (PubMed ID: 36706701)
1. The comparative analysis of selected interleukins and proinflammatory factors in CSF among de novo diagnosed patients with RRMS.
Morawiec N; Techmański T; Tracz K; Kluska A; Arendarczyk M; Baran M; Adamczyk B; Czuba Z; Bronikowska J; Adamczyk-Sowa M
Clin Neurol Neurosurg; 2023 Feb; 225():107522. PubMed ID: 36706701
[TBL] [Abstract][Full Text] [Related]
2. Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis.
Matsushita T; Tateishi T; Isobe N; Yonekawa T; Yamasaki R; Matsuse D; Murai H; Kira J
PLoS One; 2013; 8(4):e61835. PubMed ID: 23637915
[TBL] [Abstract][Full Text] [Related]
3. Relationship between cerebrospinal fluid biomarkers of inflammation and tissue damage in primary progressive multiple sclerosis.
Talbot J; Højsgaard Chow H; Mahler M; Buhelt S; Holm Hansen R; Lundell H; Vinther-Jensen T; Hellem MNN; Nielsen JE; Siebner HR; von Essen MR; Sellebjerg F
Mult Scler Relat Disord; 2022 Dec; 68():104209. PubMed ID: 36257152
[TBL] [Abstract][Full Text] [Related]
4. Tumor necrosis factor-alfa and interleukin-4 in cerbrospinal fluid and plasma in different clinical forms of multiple sclerosis.
Obradović D; Kataranovski M; Dincić E; Obradović S; Colić M
Vojnosanit Pregl; 2012 Feb; 69(2):151-6. PubMed ID: 22500369
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid IL-10 as an early stage discriminative marker between multiple sclerosis and neuro-Behçet disease.
Belghith M; Bahrini K; Kchaou M; Maghrebi O; Belal S; Barbouche MR
Cytokine; 2018 Aug; 108():160-167. PubMed ID: 29625335
[TBL] [Abstract][Full Text] [Related]
6. Presence of detectable levels of soluble HLA-G molecules in CSF of relapsing-remitting multiple sclerosis: relationship with CSF soluble HLA-I and IL-10 concentrations and MRI findings.
Fainardi E; Rizzo R; Melchiorri L; Vaghi L; Castellazzi M; Marzola A; Govoni V; Paolino E; Tola MR; Granieri E; Baricordi OR
J Neuroimmunol; 2003 Sep; 142(1-2):149-58. PubMed ID: 14512174
[TBL] [Abstract][Full Text] [Related]
7. Distinct intrathecal inflammatory signatures following relapse and anti-COVID-19 mRNA vaccination in multiple sclerosis.
Bruno A; Buttari F; Dolcetti E; Azzolini F; Borrelli A; Lauritano G; Di Caprio V; Rizzo FR; Gilio L; Galifi G; Furlan R; Finardi A; Guadalupi L; Musella A; Mandolesi G; Centonze D; Stampanoni Bassi M
Mult Scler; 2023 Oct; 29(11-12):1383-1392. PubMed ID: 37698019
[TBL] [Abstract][Full Text] [Related]
8. Sulfatide isoform pattern in cerebrospinal fluid discriminates progressive MS from relapsing-remitting MS.
Novakova L; Singh AK; Axelsson M; Ståhlman M; Adiels M; Malmeström C; Zetterberg H; Borén J; Lycke J; Cardell SL; Blomqvist M
J Neurochem; 2018 Aug; 146(3):322-332. PubMed ID: 29676479
[TBL] [Abstract][Full Text] [Related]
9. The alterations of cerebrospinal fluid TNF-alpha and TGF-beta2 levels in early relapsing-remitting multiple sclerosis.
Grzegorski T; Iwanowski P; Kozubski W; Losy J
Immunol Res; 2022 Oct; 70(5):708-713. PubMed ID: 35729473
[TBL] [Abstract][Full Text] [Related]
10. T cells producing GM-CSF and IL-13 are enriched in the cerebrospinal fluid of relapsing MS patients.
Ghezzi L; Cantoni C; Cignarella F; Bollman B; Cross AH; Salter A; Galimberti D; Cella M; Piccio L
Mult Scler; 2020 Sep; 26(10):1172-1186. PubMed ID: 31237799
[TBL] [Abstract][Full Text] [Related]
11. Circulating levels of interleukin-17A, tumor necrosis factor-alpha, interleukin-18, interleukin-10, and cognitive performance of patients with relapsing-remitting multiple sclerosis.
Trenova AG; Slavov GS; Draganova-Filipova MN; Mateva NG; Manova MG; Miteva LD; Stanilova SA
Neurol Res; 2018 Mar; 40(3):153-159. PubMed ID: 29297273
[TBL] [Abstract][Full Text] [Related]
12. Increased IL-22 in cerebrospinal fluid of neuro-behçet's disease patients.
Belghith M; Maghrebi O; Ben Laamari R; Hanachi M; Hrir S; Saied Z; Belal S; Driss A; Ben Sassi S; Boussoffara T; Barbouche MR
Cytokine; 2024 Jul; 179():156617. PubMed ID: 38631183
[TBL] [Abstract][Full Text] [Related]
13. Neuroinflammation Is Associated with GFAP and sTREM2 Levels in Multiple Sclerosis.
Azzolini F; Gilio L; Pavone L; Iezzi E; Dolcetti E; Bruno A; Buttari F; Musella A; Mandolesi G; Guadalupi L; Furlan R; Finardi A; Micillo T; Carbone F; Matarese G; Centonze D; Stampanoni Bassi M
Biomolecules; 2022 Jan; 12(2):. PubMed ID: 35204724
[No Abstract] [Full Text] [Related]
14. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis.
Ishizu T; Osoegawa M; Mei FJ; Kikuchi H; Tanaka M; Takakura Y; Minohara M; Murai H; Mihara F; Taniwaki T; Kira J
Brain; 2005 May; 128(Pt 5):988-1002. PubMed ID: 15743872
[TBL] [Abstract][Full Text] [Related]
15. Hyper-Reflecting Foci in Multiple Sclerosis Retina Associate With Macrophage/Microglia-Derived Cytokines in Cerebrospinal Fluid.
Puthenparampil M; Torresin T; Franciotta S; Marin A; De Napoli F; Mauceri VA; Miante S; Pilotto E; Midena E; Gallo P
Front Immunol; 2022; 13():852183. PubMed ID: 35664007
[TBL] [Abstract][Full Text] [Related]
16. Untreated relapsing remitting multiple sclerosis patients show antibody production against latent Epstein Barr Virus (EBV) antigens mainly in the periphery and innate immune IL-8 responses preferentially in the CNS.
Sisay S; Lopez-Lozano L; Mickunas M; Quiroga-Fernández A; Palace J; Warnes G; Alvarez-Lafuente R; Dua P; Meier UC
J Neuroimmunol; 2017 May; 306():40-45. PubMed ID: 28385186
[TBL] [Abstract][Full Text] [Related]
17. Cytokine Profile in Patients with Progressive Multiple Sclerosis and Its Association with Disease Progression and Disability.
Kallaur AP; Oliveira SR; Simão ANC; Alfieri DF; Flauzino T; Lopes J; de Carvalho Jennings Pereira WL; de Meleck Proença C; Borelli SD; Kaimen-Maciel DR; Maes M; Reiche EMV
Mol Neurobiol; 2017 May; 54(4):2950-2960. PubMed ID: 27023227
[TBL] [Abstract][Full Text] [Related]
18. CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.
Iwanowski P; Losy J; Kramer L; Wójcicka M; Kaufman E
J Neurol Sci; 2017 Sep; 380():22-26. PubMed ID: 28870573
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid detection of interleukin-1β in phase of remission predicts disease progression in multiple sclerosis.
Rossi S; Studer V; Motta C; Germani G; Macchiarulo G; Buttari F; Mancino R; Castelli M; De Chiara V; Weiss S; Martino G; Furlan R; Centonze D
J Neuroinflammation; 2014 Feb; 11():32. PubMed ID: 24548694
[TBL] [Abstract][Full Text] [Related]
20. The Comparison of the Selected Parameters of Brain Injury and Interleukins in the CSF in Patients Diagnosed De Novo with RRMS Compared to the Control Group.
Adamczyk B; Morawiec N; Mamak G; Boczek S; Brzęk D; Trędota N; Walocha P; Czuba ZP; Błachut M; Bartman W; Adamczyk-Sowa M
Diagnostics (Basel); 2023 Nov; 13(22):. PubMed ID: 37998571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
